Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Comprehensive detection of myeloma genomic abnormalities

Ola Landgren • 10 Apr 2020
Multiple Myeloma

There have been great strides made in the identification of clinically relevant molecular subgroups in multiple myeloma. In this interview, Ola Landgren, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses next-generation sequencing (NGS) for the detection of IGH translocations, relevant chromosomal gains and losses and novel genomic markers associated with poor outcomes, such as bi-allelic events involving TP53. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Ola Landgren

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
3:51
Should HR-SMM be treated before progression to NDMM?
Ola Landgren • 20 Dec 2023
3:31
ADVANCE: Dara-KRd versus KRd in patients with NDMM
Ola Landgren • 20 Dec 2023

Related Videos

4:24
Investigating production failure and out-of-specification production of CAR T-cell therapeutics
Nina Worel • 25 Apr 2024
1:14
Using MRD to accelerate drug approval in multiple myeloma
Karthik Ramasamy • 28 Apr 2024
3:54
Cilta-cel as a potential new SoC for R/R multiple myeloma: insights from the CARTITUDE-4 trial
Roberto Mina • 23 Apr 2024
1:41
CRS and neurotoxicity in bispecific antibody and CAR-T therapy for multiple myeloma
Eden Biltibo • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals